COPD Exacerbation: Clinical Trials

7 trials for COPD Exacerbation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 47Completed 7

Follow COPD Exacerbation: new trials by email Literature Review of COPD Exacerbation trials Research Report on COPD Exacerbation

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause
Long acting muscarinic antagonists (LAMAs) in the evening - COPD Exacerbation
Phase 4CompletedChronic Obstructive Pulmonary Disease Trial Network, Denmark100112023-01-272025-02-19
Eosinophil-guided Reduction of Inhaled Corticosteroids
Azithromycin, ICS - COPD, Inhaled Corticosteroid
Phase 4CompletedChronic Obstructive Pulmonary Disease Trial Network, Denmark4442021-06-282026-01-28
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) - COPD Exacerbation
Phase 4CompletedUniversity of Tennessee Graduate School of Medicine602020-12-092026-08-03
Stratified TreAtment to Reduce Risk in COPD
Prednisolone - COPD Exacerbation
Phase 4CompletedUniversity of Oxford2032017-11-022020-07-21
Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB)
ceftidoren, levofloxacin - COPD Exacerbation
Phase 4CompletedUniversity of Milan402012-01-012012-06-05
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
Roflumilast, Placebo - COPD, COPD Exacerbation
Phase 4CompletedAstraZeneca23542011-09-302017-04-13
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD
Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day - COPD Exacerbation
Phase 4CompletedFadoi Foundation, Italy2582009-05-012025-02-11

Narrower conditions

Pulmonary Disease, Chronic Obstructive (2)  ·  Bronchitis, Chronic (1)  ·  Inflammation (1)  ·  Lung Diseases (1)  ·  Pneumonia (1)  ·  Respiration Disorders (1)

Broader conditions

Chronic Disease (3)  ·  Disease Attributes (3)  ·  Lung Diseases, Obstructive (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Respiratory Tract Diseases (3)  ·  Infections (2)  ·  Lung Diseases (2)  ·  Respiratory Tract Infections (2)  ·  Bronchial Diseases (1)  ·  Bronchitis (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Interventions

Azithromycin (1)  ·  Formoterol Fumarate (1)  ·  Levofloxacin (1)  ·  Prednisolone (1)  ·  Roflumilast (1)  ·  revefenacin (1)

Sponsors

Chronic Obstructive Pulmonary Disease Trial Network, Denmark (2)  ·  AstraZeneca (1)  ·  Fadoi Foundation, Italy (1)  ·  University of Milan (1)  ·  University of Oxford (1)  ·  University of Tennessee Graduate School of Medicine (1)

Countries

Italy (3)  ·  Denmark (2)  ·  United States (2)  ·  Argentina (1)  ·  Canada (1)  ·  Chile (1)  ·  Colombia (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  Peru (1)  ·  Philippines (1)  ·  Romania (1)  ·  Russia (1)  ·  Serbia (1)  ·  Spain (1)

Top investigators

Francesco B Blasi, MD (1)  ·  Gualberto GG Gussoni, MD, PhD (1)  ·  Mona Bafadhel, MBChB, PhD (1)

Results publications

PMID 27585384, PMID 29579254, PMID 29763572, PMID 39165373, PMID 40898355, PMID 41340061, PMID 42548489